Kidney Cancer Journal 87
tic factor for survival in patients with metastatic renal cell carcinoma.
Cancer 2006; 107:1793–800.
6. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin
6 levels in patients with reactive thrombocytosis. Br J Haematol
1991; 79:286–90.
7. Pérez-Valderrama B, Arija A, A J, et al. Validation of the International
Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic
model for first-line pazopanib in metastatic renal carcinoma: the
Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann
Oncol 2016; 27:706–11.
8. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell
Carcinoma Database Consortium model as a prognostic tool in patients
with metastatic renal cell carcinoma previously treated with first-line targeted
therapy: a population-based study. Lancet Oncol 2015;16:293–300.
9. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in
Metastatic Renal-Cell Carcinoma. New England Journal of Medicine 2013;
369:722–31.
10. Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences
for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics
2011;29:977–88.
11. Wong MK, Mohamed AF, Hauber AB, et al. Patients rank toxicity
against progression free survival in second-line treatment of advanced
renal cell carcinoma. J Med Econ 2012;15:1139–48.
12. Escudier B, Porta C, Bono P, et al. Randomized, controlled, doubleblind,
cross-over trial assessing treatment preference for pazopanib versus
sunitinib in patients with metastatic renal cell carcinoma: PISCES
Study. J Clin Oncol 2014; 32:1412–8.
13. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes
and the evolution of adverse event reporting in oncology. J Clin Oncol
2007; 25:5121–7.
14. Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of
sunitinib on an intermittent versus continuous dosing schedule as firstline
therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30:
1371–7.
15. Lee JL, Kim MK, Park I, et al. RandomizEd phase II trial of Sunitinib
four weeks on and two weeks off versus Two weeks on and One week off
in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann
Oncol 2015; 26:2300–5.
16. Kim J-W, Lee MN, Jeong B-C, Oh S-H, Kook M-S, Koh J-T. Chemical
inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation
and bone regeneration. Eur J Pharmacol 2017; 806:10–7.
17. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus
Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:
1814–23.
18. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib
As Initial Targeted Therapy for Patients With Metastatic Renal Cell
Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN
Trial. J Clin Oncol 2017; 35:591–7.
19. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib
as initial therapy for metastatic renal cell carcinoma of intermediate or
poor risk (Alliance A031203 CABOSUN randomised trial): Progressionfree
survival by independent review and overall survival update. European
Journal of Cancer 2018; 94:115–25.
20. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab
versus Sunitinib in Advanced Renal-Cell Carcinoma. New England
Journal of Medicine 2018; 378:1277–90.
21. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus
Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of
Medicine 2015; 373:1803–13.
22. Voss MH, Hakimi AA, Pham CG, et al. Tumor Genetic Analyses of Patients
with Metastatic Renal Cell Carcinoma and Extended Benefit from
mTOR Inhibitor Therapy. Clin Cancer Res 2014;20:1955–64.
23. Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2,
and MTOR Are Associated with Response to Rapalogs in Patients with
Metastatic Renal Cell Carcinoma. Clin Cancer Res 2016;22:2445–52.
24. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response
to immune checkpoint therapies in clear cell renal cell carcinoma. Science
2018;359:801–6.
25. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and
molecular correlates of response to atezolizumab alone or in combination
with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med
2018;24:749–57. KCJ